Why now

The original draft undersold this. The June cycle is not just a trade pickup. Heartseed announced first-patient dosing in a Phase I/II EMERALD study using catheter delivery of allogeneic iPSC-derived cardiomyocyte spheroids, with the first patient reportedly treated in late March and discharged after an uneventful early course. That makes the timing stronger: a first-in-human or first-in-world delivery-method milestone has moved from lab platform to patient dosing, while still having zero efficacy proof.

Why now

This is much stronger than a generic DMD update because two clocks are now running: Capricor announced five-year HOPE-2 open-label extension data for deramiocel and, separately, an FDA advisory committee meeting was scheduled for July 29 with an August 22 PDUFA target date. That gives VV a clear 'watch before the regulator decides' moment. The human frame is preservation of time in a progressive disease, but the source is company-reported and must be caveated.

Why now

A fresh hospital patient story makes CAR-T feel like a human process, not just a platform technology.